.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC24_Ticagrelor.Ticagrelor .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC24_Ticagrelor.Ticagrelor| name: | Ticagrelor |
| ATC code: | B01AC24 | route: | oral |
| n-compartments | 2 |
Ticagrelor is a direct-acting, oral, reversible P2Y12 receptor antagonist used as an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome or a history of myocardial infarction. Approved for clinical use in many countries including the US and EU.
Pharmacokinetic parameters reported for healthy adult subjects after single and multiple oral doses.
Amilon, C, et al., & Hamrén, B (2019). Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease. Clinical pharmacokinetics 58(10) 1295–1307. DOI:10.1007/s40262-019-00758-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30972696
Röshammar, D, et al., & Hamrén, B (2017). Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . International journal of clinical pharmacology and therapeutics 55(5) 416–424. DOI:10.5414/CP202748 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28139972
Liu, S, et al., & Tian, X (2018). Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects. European journal of clinical pharmacology 74(6) 745–754. DOI:10.1007/s00228-018-2427-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29442148